EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Neuregulin 4 in Insulin Resistance: Mechanisms, Controversies, and Therapeutic Perspectives

Zhiheng Qiao iD, Xiaocan Gai, Hongyang He, Guoliang Ji, Haixin Zhang iD, Shumin Liu

Diabetes, Metabolic Syndrome and Obesity · 2026-08 · Volume 19 · 1-19

DOI: 10.2147/dmso.s619218 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes, Metabolic Syndrome and Obesity, 2026-08. Verfasst von Zhiheng Qiao und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Graduate Students, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Neuregulin 4 (Nrg4) is an adipocyte-secreted factor belonging to the epidermal growth factor (EGF) family, and has been implicated in the regulation of metabolic homeostasis, particularly insulin resistance (IR). Preclinical studies have demonstrated that Nrg4 activates ErbB4 receptor tyrosine kinase and downstream signaling pathways such as PI3K/AKT and AMPK/mTOR, leading to inhibition of inflammatory responses, regulation of autophagy, and protection of mitochondrial function, all of which can ameliorate IR in animal models. However, clinical evidence regarding Nrg4's association with insulin sensitivity in humans remains inconsistent and even contradictory. While some studies report reduced circulating Nrg4 levels in patients with type 2 diabetes and a positive correlation with insulin sensitivity, others have found a negative correlation, suggesting that Nrg4 may play context-dependent or even opposing roles. This review aims to provide a comprehensive overview of the physiological characteristics and signaling mechanisms of Nrg4, critically evaluate the evidence for its role in improving IR, and explicitly address the existing discrepancies between preclinical and clinical findings. Finally, we discuss the therapeutic potential and safety considerations of targeting Nrg4 for IR and related metabolic diseases, acknowledging the current limitations and unresolved controversies.

Schlagwörter

Stichwörter der Autor:innen

Nrg4adipokineshyperinsulinemiainsulin resistancesignaling pathways

Autor:innen und Institutionen

  • School of Graduate Students, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China.
  • Basic Medical College, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150040, People's Republic of China.

ORCID-Profile: Zhiheng Qiao, Haixin Zhang

Zitieren

APA

Qiao, Z., Gai, X., He, H., Ji, G., Zhang, H., & Liu, S. (2026). Neuregulin 4 in Insulin Resistance: Mechanisms, Controversies, and Therapeutic Perspectives. Diabetes, Metabolic Syndrome and Obesity, Volume 19, 1-19. https://doi.org/10.2147/dmso.s619218

Vancouver

Qiao Z, Gai X, He H, Ji G, Zhang H, Liu S. Neuregulin 4 in Insulin Resistance: Mechanisms, Controversies, and Therapeutic Perspectives. Diabetes, Metabolic Syndrome and Obesity. 2026;Volume 19:1-19. doi:10.2147/dmso.s619218

BibTeX
@article{Qiao2026,
  author = {Qiao, Zhiheng and Gai, Xiaocan and He, Hongyang and Ji, Guoliang and Zhang, Haixin and Liu, Shumin},
  title = {Neuregulin 4 in Insulin Resistance: Mechanisms, Controversies, and Therapeutic Perspectives},
  journal = {Diabetes, Metabolic Syndrome and Obesity},
  year = {2026},
  volume = {Volume 19},
  pages = {1--19},
  doi = {10.2147/dmso.s619218}
}
Kostenlos starten →